Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A modified gene trap approach for improved high-throughput cancer drug discovery.

Morris SM, Mhyre AJ, Carmack SS, Myers CH, Burns C, Ye W, Ferrer M, Olson JM, Klinghoffer RA.

Oncogene. 2018 Aug;37(31):4226-4238. doi: 10.1038/s41388-018-0274-4. Epub 2018 May 2.

2.

Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.

Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, Burns C, Ditzler SH, Dixon CP, Beirne E, Gillespie KC, Kleinman EF, Klinghoffer RA.

Sci Rep. 2017 Dec 21;7(1):18007. doi: 10.1038/s41598-017-18368-w.

3.

Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation.

Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR, Grenley MO, Beirne E, Watts KL, Keener A, Thirstrup DJ, Tretyak I, Ditzler SH, Tripp CD, Choy K, Gillings S, Breit MN, Meleo KA, Rizzo V, Herrera CL, Perry JA, Amaravadi RK, Olson JM, Klinghoffer RA.

Cancer Res. 2017 Jun 1;77(11):2869-2880. doi: 10.1158/0008-5472.CAN-17-0084. Epub 2017 Mar 31.

4.

A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo.

Dey J, Kerwin WS, Grenley MO, Casalini JR, Tretyak I, Ditzler SH, Thirstrup DJ, Frazier JP, Pierce DW, Carleton M, Klinghoffer RA.

PLoS One. 2016 Jun 30;11(6):e0158617. doi: 10.1371/journal.pone.0158617. eCollection 2016.

5.

Predicting responses to chemotherapy in the context that matters - the patient.

Moreno-Gonzalez A, Olson JM, Klinghoffer RA.

Mol Cell Oncol. 2015 Jun 10;3(1):e1057315. doi: 10.1080/23723556.2015.1057315. eCollection 2016 Jan.

6.

Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model.

Frazier JP, Beirne E, Ditzler SH, Tretyak I, Casalini JR, Thirstrup DJ, Knoblaugh S, Ward JG, Tripp CD, Klinghoffer RA.

Vet Comp Oncol. 2017 Sep;15(3):754-763. doi: 10.1111/vco.12215. Epub 2016 Mar 18.

PMID:
26991424
7.

Minimally invasive in tumor multidrug comparative analysis with contrast-enhanced MRI in mice.

Kerwin WS, Tretyak I, Grenley MO, You S, Hatton BA, Moreno-Gonzalez A, Thirstrup DJ, Klinghoffer RA.

Magn Reson Med. 2016 Sep;76(3):946-52. doi: 10.1002/mrm.25978. Epub 2015 Sep 12.

PMID:
26362018
8.

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.

Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, Chopra R.

Cancer Chemother Pharmacol. 2015 Oct;76(4):699-712. doi: 10.1007/s00280-015-2833-5. Epub 2015 Aug 1.

9.

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A, Strand AD, Kerwin WS, Casalini JR, Thirstrup DJ, You S, Morris SM, Watts KL, Veiseh M, Grenley MO, Tretyak I, Dey J, Carleton M, Beirne E, Pedro KD, Ditzler SH, Girard EJ, Deckwerth TL, Bertout JA, Meleo KA, Filvaroff EH, Chopra R, Press OW, Olson JM.

Sci Transl Med. 2015 Apr 22;7(284):284ra58. doi: 10.1126/scitranslmed.aaa7489.

10.

Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.

Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, BraƱa I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J.

Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15.

11.

Protein tyrosine phosphatase epsilon affects body weight by downregulating leptin signaling in a phosphorylation-dependent manner.

Rousso-Noori L, Knobler H, Levy-Apter E, Kuperman Y, Neufeld-Cohen A, Keshet Y, Akepati VR, Klinghoffer RA, Chen A, Elson A.

Cell Metab. 2011 May 4;13(5):562-72. doi: 10.1016/j.cmet.2011.02.017.

12.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

13.

Reduced seed region-based off-target activity with lentivirus-mediated RNAi.

Klinghoffer RA, Magnus J, Schelter J, Mehaffey M, Coleman C, Cleary MA.

RNA. 2010 May;16(5):879-84. doi: 10.1261/rna.1977810. Epub 2010 Mar 26.

14.

A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/GSK3 signaling.

Klinghoffer RA, Frazier J, Annis J, Berndt JD, Roberts BS, Arthur WT, Lacson R, Zhang XD, Ferrer M, Moon RT, Cleary MA.

PLoS One. 2009 Sep 3;4(9):e6892. doi: 10.1371/journal.pone.0006892.

15.

An optimized lentivirus-mediated RNAi screen reveals kinase modulators of kinesin-5 inhibitor sensitivity.

Klinghoffer RA, Roberts B, Annis J, Frazier J, Lewis P, Linsley PS, Cleary MA.

Assay Drug Dev Technol. 2008 Feb;6(1):105-19. doi: 10.1089/adt.2007.106.

PMID:
18205551
16.

Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms.

Hamilton TG, Klinghoffer RA, Corrin PD, Soriano P.

Mol Cell Biol. 2003 Jun;23(11):4013-25.

17.
18.
19.

The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions.

Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Shani M, Soriano P.

Mol Cell. 2001 Feb;7(2):343-54.

20.

Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase Cgamma signaling pathways.

Tallquist MD, Klinghoffer RA, Heuchel R, Mueting-Nelsen PF, Corrin PD, Heldin CH, Johnson RJ, Soriano P.

Genes Dev. 2000 Dec 15;14(24):3179-90.

21.

Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression.

Rosenkranz S, Ikuno Y, Leong FL, Klinghoffer RA, Miyake S, Band H, Kazlauskas A.

J Biol Chem. 2000 Mar 31;275(13):9620-7.

22.

Growth factor signaling pathways in vascular development.

Tallquist MD, Soriano P, Klinghoffer RA.

Oncogene. 1999 Dec 20;18(55):7917-32. Review.

23.

Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion.

Davy A, Gale NW, Murray EW, Klinghoffer RA, Soriano P, Feuerstein C, Robbins SM.

Genes Dev. 1999 Dec 1;13(23):3125-35.

24.

Src family kinases are required for integrin but not PDGFR signal transduction.

Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P.

EMBO J. 1999 May 4;18(9):2459-71.

26.

Identification of a putative Syp substrate, the PDGF beta receptor.

Klinghoffer RA, Kazlauskas A.

J Biol Chem. 1995 Sep 22;270(38):22208-17.

Supplemental Content

Loading ...
Support Center